Stocks Screeners Features Pricing
Sign In Get Started

Steris Stock Analysis

NYSE: STE | Health Care | Health Care Equipment
Price $210.19 +$0.43 (+0.20%)
P/E Ratio 27.9 TTM
52-Week Range
Low $195 High $269
Market Cap $20.75B USD
ROE 10.9% Annual

Market data as of Jun 3, 2026 · Financials as of Mar 2026

Published May 23, 2026 · Updated May 27, 2026

Let's break down Steris (STE) — from its financial performance to how the market is valuing the stock.

Top-Line Growth

Steris reported revenue of $5.94B in FY2026, a 8.7% increase from $5.46B in FY2025.

The 10-year revenue CAGR of 10.2% is a good number — Steris's top line has expanded meaningfully from $2.24B to $5.94B.

Steris's $5.94B revenue base puts it in the mid-cap bracket among US health care companies.

Steris has posted revenue growth for 10 consecutive years — that's a sustained trend, not a one-off.

Revenue Trend
Year Revenue YoY %
FY2026 $5.94B +8.7%
FY2025 $5.46B +6.2%
FY2024 $5.14B +13.3%
FY2023 $4.54B +7.4%
FY2022 $4.22B +35.9%

Explore the full 10-year revenue trend with interactive charts

Business Segments

Looking under the hood at Steris's revenue mix for FY2025.

Steris Business Segment Performance (FY2025)
Segment Revenue % of Total
Product $2.87B 52.6%
Service $2.59B 47.4%

Product makes up 52.6% of revenue, clearly the primary business for Steris.

Looking at geographic exposure, Steris's revenue comes from United States (73%), Other foreign locations (25%), and Ireland (2%).

Profitability Analysis

A 27.7% improvement in net income took Steris's bottom line to $785.1M in FY2026.

The company squeezed out better margins in FY2026, with net margin at 13.2% versus 11.3% in FY2025.

On a per-share basis, diluted earnings were $7.93 in FY2026 versus $6.20 in FY2025.

See Steris's full margin history and earnings breakdown

How Steris Returns Cash to Shareholders

In FY2026, Steris distributed $2.45 per share in dividends (1.13% yield).

With 10+ consecutive years of dividend payments, Steris has a proven track record of returning cash to shareholders.

A 30.9% payout ratio is well-managed — Steris returns a healthy share of earnings while keeping enough for growth.

Dividend Per Share & Payout Ratio
Year DPS Payout Ratio
FY2026 $2.45 30.9%
FY2025 $2.22 35.8%
FY2024 $2.02 53.0%
FY2023 $1.83 171.1%
FY2022 $1.66 66.9%

On the buyback front, Steris has spent $1.15B repurchasing shares over 11 years, reducing the float and boosting per-share metrics.

View the full share repurchase and dilution trend

Financial Health

Financial Position Summary (FY2026)
Metric Value
Cash & Short-term Investments $439.6M
Total Debt $1.93B
Shareholders' Equity $7.20B
Total Assets $10.74B
Debt-to-Equity Ratio 0.27x
Current Ratio 2.09x
Interest Coverage 18.2x
Free Cash Flow (TTM) $972.4M

Balance sheet strength is evident: $439.6M in cash and equivalents, $1.93B in total debt, and a manageable 0.27x D/E ratio.

At 2.09x, Steris's current ratio suggests solid short-term financial flexibility.

With interest coverage at 18.2x, Steris's operating income comfortably exceeds its interest obligations.

Steris generated $972.4M in free cash flow, providing ample capacity for dividends, buybacks, and debt reduction.

Explore Steris's full balance sheet and cash flow analysis below

Steris reported a headcount of 18,000 in FY2025, about $303.3K in revenue per employee.

See Steris's full employee count history and revenue per employee

What Is Steris Worth?

Let's put a fair value on Steris using three independent valuation approaches.

Steris shares are currently trading at $210.19.

The P/E Ratio model estimates an intrinsic value of $388, implying a 45.8% upside from the current price.

We also calculate intrinsic value using the DCF and EPS Growth models. Sign up to see the full breakdown with fair value estimates.

Valuation Models
Model Est. Fair Value vs. Current Price
P/E Ratio $388 45.8% upside to fair value
DCF Upgrade Upgrade
EPS Growth Upgrade Upgrade

Investment Snapshot

What should investors take away from Steris's (STE) latest numbers? Here's the summary.

Revenue of $5.94B in FY2026, up 8.7% year-over-year.

Long-term revenue has been compounding at 10.2% annually over 10 years.

The company is profitable, with a net margin of 13.2% and net income of $785.1M.

Returned $477.3M to shareholders in FY2026 through dividends and/or buybacks.

Conservative balance sheet with a D/E ratio of 0.27x.

The P/E Ratio model implies 45.8% upside to fair value. The remaining 2 models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.

The detailed charts and valuation models below provide a deeper look at Steris's financial trajectory.

Frequently Asked Questions

Is Steris's revenue growing?
Steris's revenue was $5.94B in FY2026, up 8.7% from the prior year.
What is Steris's net income?
Steris (STE) posted net income of $785.1M in FY2026.
Does Steris pay a dividend?
Yes, Steris pays a regular dividend to shareholders.
Is Steris stock overvalued?
Based on the P/E ratio model, Steris appears undervalued — trading at a 45% discount to its estimated fair value of $391.
What industry is Steris in?
Steris is in the Health Care Equipment industry within the Health Care sector.

What does Steris do?

STERIS provides infection prevention, sterilization, and procedural products and services to hospitals, healthcare providers, and pharmaceutical manufacturers. Its four segments — Healthcare, Applied Sterilization Technologies (AST), Life Sciences, and Dental — span sterile processing equipment and consumables, contract sterilization through a ~50-facility global network, and dental instruments and infection control products.

Detailed Charts

Steris Performance

2-year trend showing revenue, gross profit, and net profit

FY2025 – FY2026

Steris's revenue grew 8.7% to $5.94B and net profit grew 27.7% to $785.10M YoY in FY2026, indicating moderate business momentum.

Understanding Company Performance

Revenue is Steris's total income from operations. Gross Profit is revenue minus cost of goods sold — the higher it is relative to revenue, the stronger the company's pricing power. Net Profit is the bottom line after all expenses, taxes, and interest. Consistent growth across all three signals a healthy, expanding business. Compare with peers in the same sector.

Is Steris Profitable?

2-year trend showing gross, operating, and net profit margins

FY2025 – FY2026

Steris's net profit margin of 13.2% in FY2026 reflects moderate profitability, with operating margin at 18.6% and gross margin at 44.2%.

Understanding Profitability Margins

Gross Profit Margin (GPM) shows what percentage of Steris's revenue remains after direct production costs. Operating Profit Margin (OPM) factors in operating expenses like R&D and SG&A. Net Profit Margin (NPM) is the final profitability after all costs including interest and taxes. Stable or improving margins indicate pricing power and cost discipline.

Steris Revenue & Earnings Growth

2-year trend showing revenue and diluted EPS

FY2025 – FY2026

Steris's revenue grew 8.7% YoY in FY2026, with EPS growing 27.9%, moderate growth.

Understanding Revenue & Earnings Growth

Revenue is Steris's total income from operations — the top line. Diluted EPS (Earnings Per Share) is net income divided by all shares that could exist if stock options, RSUs, and convertibles were exercised. Revenue shows how fast the business is growing; EPS shows how much of that growth reaches shareholders after all costs and dilution. Healthy companies tend to grow both in tandem; when revenue grows but EPS shrinks, margins are compressing. Use our stock screener to compare growth profiles across companies.

Steris Compound Annual Growth Rate (CAGR)

Metric 1-Year 5-Year 10-Year
Revenue +8.7% +13.8% +10.2%
Net Income +27.7% +14.6% +21.6%
EPS +27.9% +11.4% +17.7%
Share Price -12.8% +3.0% +12.7%

Steris's 10-year revenue CAGR of 10.2% reflects healthy long-term growth, with EPS CAGR of 17.7% outpacing revenue, indicating improving profitability. The share price has compounded at 12.7% annually over a comparable period, broadly tracking fundamentals.

Steris Quarterly Performance

Quarterly revenue and net income with a weekly share-price overlay

Upgrade to see the full 5 years (20 quarters) of quarterly data.

FY2026

How to Read Quarterly Performance

Quarterly revenue and net income are Steris's most recent three-month results. Each bar shows net income nested inside revenue, since profit is the slice of revenue left after all costs; the taller the green portion relative to the blue, the more of each sales dollar reached the bottom line. A bar below zero is a quarterly loss.

For a long-term view, compare each quarter with the same quarter a year earlier (year-over-year), not with the previous quarter — sequential change is mostly seasonality (for many businesses the holiday quarter is always the biggest). Then watch the trend across several years: is year-over-year revenue growth accelerating or fading; is net income growing at least as fast as revenue (expanding vs compressing margins)? One quarter is noise — the multi-quarter trend is the signal.

Steris Share Price vs Book Value

Steris (STE) share price vs book value per share — FY2017 – FY2026

Understanding Share Price vs Book Value

Share Price is what the market pays per share of Steris. Book Value per Share (BVPS) is the company's net equity divided by diluted shares — the accounting floor if the company were liquidated today. When price tracks close to book value the market sees the company as a steady asset; when price runs far above book the market is paying up for expected future earnings. For banks, book value is the primary valuation anchor; for most other companies it's one signal among many.

Unlock Valuation Analysis

Get fair value estimates from multiple valuation models and see whether a stock is undervalued or overvalued.

  • Multi-model fair value estimates (P/E, DCF, EPS Growth)
  • Undervalued/overvalued assessment with upside potential
  • Compare fair values across methodologies

Steris Free Cash Flow

2-year trend — cash generated after reinvestment

FY2025 – FY2026

Steris's free cash flow of $972.40M in FY2026 represents a 16.4% FCF margin — healthy cash generation supporting dividends, buybacks, or debt reduction.

Understanding Free Cash Flow

Free Cash Flow (FCF) is Steris's operating cash flow minus capital expenditure — the cash left over after maintaining and growing the business. Unlike net profit, FCF strips out non-cash items (depreciation, stock-based compensation) and includes actual cash spent on assets. Positive FCF means the company can pay dividends, buy back shares, reduce debt, or make acquisitions without raising capital. Consistently negative FCF signals the company is burning cash and may need external funding.

Steris Financial Ratios

Balance sheet strength and debt servicing capacity

FY2025 – FY2026

Debt-to-Equity

0.27

▼ from 0.36

Current Ratio

2.09

▲ from 1.96

Interest Coverage

18.2x

▲ from 10.0x

Steris's a debt-to-equity ratio of 0.27, a current ratio of 2.09, interest coverage of 18.2x in FY2026 indicate a conservatively financed balance sheet with strong debt servicing capacity.

Understanding Financial Health

Debt-to-Equity (D/E) measures how much debt the company carries relative to shareholder equity — lower means less leverage risk. Current Ratio divides current assets by current liabilities — above 1.0 means the company can cover short-term obligations. Interest Coverage is operating income divided by interest expense — higher means the company earns well above its debt payments. Together these three metrics reveal whether a company can weather downturns without financial distress.

Steris Shares Outstanding

Diluted share count per fiscal year — labels show year-over-year change

FY2025 – FY2026

Steris's diluted shares decreased modestly by 0.4% YoY in FY2026 — a small net buyback.

Understanding Shares Outstanding

Diluted shares outstanding counts every share of Steris that could exist if all stock options, RSUs, and convertibles were exercised. A shrinking count signals buybacks (returning cash to shareholders by reducing the denominator of EPS). A growing count signals dilution — usually from stock-based compensation, secondary offerings, or stock-funded acquisitions. Routine 1–2% growth is typical at large-cap tech companies that pay employees in equity; sustained growth above 5% warrants a look at the cause.

Unlock Full Analysis

Get the complete 10-year financial history with interactive charts and growth analysis.

Related Stocks